TAQA Arabia S.A.E. (EGX:TAQA)
Egypt · Delayed Price · Currency is EGP 12.50
+0.02 (0.16%)
At close: Jul 31, 2025
Intra-Cellular Therapies Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
| 20,707 | 18,905 | 13,464 | 10,728 | 9,102 | 7,924 | Upgrade | |
Revenue Growth (YoY) | 46.84% | 40.41% | 25.50% | 17.86% | 14.87% | 2.58% | Upgrade |
Operations & Maintenance | 27.93 | 27.93 | 20.43 | 14.71 | 2.14 | 1.79 | Upgrade |
Selling, General & Admin | 665.21 | 588.57 | 457.11 | 299 | 259.72 | 212.11 | Upgrade |
Provision for Bad Debts | 26.27 | 23.94 | 5.95 | 0.79 | - | - | Upgrade |
Other Operating Expenses | 18,412 | 16,802 | 11,912 | 9,586 | 8,165 | 7,100 | Upgrade |
Total Operating Expenses | 19,131 | 17,443 | 12,396 | 9,901 | 8,427 | 7,313 | Upgrade |
Operating Income | 1,576 | 1,462 | 1,068 | 826.85 | 674.69 | 610.25 | Upgrade |
Interest Expense | -1,264 | -1,348 | -1,441 | -872.67 | -493.17 | -363.18 | Upgrade |
Interest Income | 787.38 | 886.55 | 1,272 | 796.58 | 535.59 | 357.21 | Upgrade |
Net Interest Expense | -477.03 | -461.52 | -168.66 | -76.09 | 42.42 | -5.97 | Upgrade |
Currency Exchange Gain (Loss) | 44.96 | 72.67 | -2.16 | 31.14 | -0.82 | -9.4 | Upgrade |
Other Non-Operating Income (Expenses) | - | - | 1.12 | 16.94 | - | - | Upgrade |
EBT Excluding Unusual Items | 1,144 | 1,073 | 898.28 | 798.84 | 716.29 | 594.88 | Upgrade |
Gain (Loss) on Sale of Assets | 1.91 | 1.91 | 1.83 | 3.44 | - | - | Upgrade |
Other Unusual Items | - | - | 0.1 | - | - | - | Upgrade |
Pretax Income | 1,146 | 1,075 | 900.22 | 802.29 | 716.29 | 594.88 | Upgrade |
Income Tax Expense | 289.72 | 285.26 | 258.73 | 200.43 | 181.95 | 147.42 | Upgrade |
Earnings From Continuing Ops. | 855.86 | 789.91 | 641.49 | 601.85 | 534.34 | 447.46 | Upgrade |
Minority Interest in Earnings | -120.52 | -87.88 | -84.28 | -63.24 | -54.46 | -37.47 | Upgrade |
Net Income | 735.34 | 702.03 | 557.21 | 538.61 | 479.88 | 409.99 | Upgrade |
Net Income to Common | 735.34 | 702.03 | 557.21 | 538.61 | 479.88 | 409.99 | Upgrade |
Net Income Growth | 28.64% | 25.99% | 3.45% | 12.24% | 17.05% | 12.27% | Upgrade |
Shares Outstanding (Basic) | 1,352 | 1,352 | 1,352 | 1,352 | 1,352 | 1,352 | Upgrade |
Shares Outstanding (Diluted) | 1,352 | 1,352 | 1,352 | 1,352 | 1,352 | 1,352 | Upgrade |
EPS (Basic) | 0.54 | 0.52 | 0.41 | 0.40 | 0.35 | 0.30 | Upgrade |
EPS (Diluted) | 0.54 | 0.52 | 0.41 | 0.40 | 0.35 | 0.30 | Upgrade |
EPS Growth | 28.64% | 25.97% | 3.52% | 12.16% | 17.05% | 92.83% | Upgrade |
Free Cash Flow | 1,672 | 563.35 | 182.27 | -392 | -215.57 | 731.35 | Upgrade |
Free Cash Flow Per Share | 1.24 | 0.42 | 0.14 | -0.29 | -0.16 | 0.54 | Upgrade |
Profit Margin | 3.55% | 3.71% | 4.14% | 5.02% | 5.27% | 5.17% | Upgrade |
Free Cash Flow Margin | 8.07% | 2.98% | 1.35% | -3.65% | -2.37% | 9.23% | Upgrade |
EBITDA | 1,953 | 1,812 | 1,331 | 1,023 | 825.44 | 733.18 | Upgrade |
EBITDA Margin | 9.43% | 9.59% | 9.89% | 9.53% | 9.07% | 9.25% | Upgrade |
D&A For EBITDA | 377.17 | 350.31 | 263.52 | 195.77 | 150.75 | 122.93 | Upgrade |
EBIT | 1,576 | 1,462 | 1,068 | 826.85 | 674.69 | 610.25 | Upgrade |
EBIT Margin | 7.61% | 7.73% | 7.93% | 7.71% | 7.41% | 7.70% | Upgrade |
Effective Tax Rate | 25.29% | 26.53% | 28.74% | 24.98% | 25.40% | 24.78% | Upgrade |
Source: S&P Global Market Intelligence. Utility template. Financial Sources.